Analyst: Darzalex sales figures could result in Genmab upgrade

Sales of the Genmab-developed drug Darzalex, which is in-licensed to Jonhson & Johson, have gone so well in the third quarter that one analyst thinks a guidance upgrade from Genmab could likely be on its way.
Photo: Sydbank/PR
Photo: Sydbank/PR
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

The bone marrow cancer treatment Darzalex exceeded analysts' third quarter sales expectations with around DKK 850m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading